Introduction: There is a need for ADC payloads with an improved therapeutic index, consequently we have coupled potent and selective inhibitors of NMT to trastuzumab to test their potential in both in ...
You do not currently have access to this content.
Background: Activating RET alterations drive oncogenic signaling in lung, thyroid, and other solid tumors.Until recently, only two RET tyrosine kinase inhibitor (TKI), BLU-667 and LOXO-292, had ...
Abstract. High-throughput screening (HTS) of cereblon (CRBN) molecular glue (MG)-biased libraries remains a key strategy for proof-of-concept studies and hit identification against emerging targets.
Background: LIV-1, also known as SLC39A6 or ZIP6, is a transmembrane protein belonging to the zinc transporter family. LIV-1 is a promising target for antibody-drug conjugate (ADC) therapy due to its ...
Cancer Res (2023) 83 (8_Supplement): LB078. Sarcomas are a broad group of soft tissue and bone cancers that can be difficult to treat leading to a high mortality rate. Sarcomas comprise two broad ...
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio ® (avelumab), a ...
Cancer Discov (2026) 16 (7): OF1.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results